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A rapidly aging population in Korea has led to increased attention in the field of anti-aging medicine. The purpose 
of anti-aging medicine is to slow, stop, or reverse the aging process and its associated effects, such as disability and 
frailty. Anti-aging medicine is emerging as a growing industry, but many supplements or protocols are available 
that do not have scientific evidence to support their claims. In this review, the mechanisms of action and the clini-
cal implications of anti-aging interventions were examined and explained. Calorie restriction mimetics define 
compounds that imitate the outcome of calorie restriction, including an activator of AMP protein kinase (metfor-
min), inhibitor of growth hormone/insulin-like growth factor-1 axis (pegvisomant), inhibitor of mammalian target 
of rapamycin (rapamycin), and activator of the sirtuin pathway (resveratrol). Hormonal replacement has also been 
widely used in the elderly population to improve their quality of life. Manipulating healthy gut microbiota through 
prebiotic/probiotics or fecal microbiota transplantation has significant potential in anti-aging medicine. Vitamin D 
is expected to be a primary anti-aging medicine in the near future due to its numerous positive effects in the elderly 
population.
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INTRODUCTION
An increasing population age, defined as a rising median age in the 
population, has emerged as one of the most significant challenges and 
financial burdens for many countries. The Korean population is rapid-
ly aging and becoming an aged society, as are other developed coun-
tries. As the population of Korea is rapidly aging due to low fertility and 
a long life span, the problem of the elderly is becoming a social issue. 
Approximately 14.3% of the Korean population was aged 65 or older in 
2018, and the percentage is expected to rapidly rise to 20.3% in 2027 
and 34.4% in 2050.1) Recent advances in science and medicine have 
led to research that elucidates aging mechanisms, and anti-aging 
medicine is emerging as a growing industry. The definition of anti-ag-
ing medicine is as follows: “measures taken to slow, stop, or even re-
verse phenomena related to aging, as well as to increase life span.”2) 
Anti-aging related health supplements, cosmetics, and hormone re-
placement therapy (HRT) have been developed and advertised in the 
media, but there is still a lack of scientific evidence. In this article, we 
will review the behavioral, dietary, and pharmacological approaches 
of anti-aging medicine.
CALORIE RESTRICTION AND MIMETICS
Among all the anti-aging interventions, dietary interventions have 
shown the greatest potential. Calorie restriction, without malnourish-
ing the individual, slows the aging process and expands the average 
and maximal lifespan in animals of diverse origin.3,4) McCay et al.5) re-
ported that restricting food intake in rats extended the median and 
maximum life span and decreased the onset and severity of chronic 
diseases. Subsequent findings emphasized that calorie restriction has 
effects on life-span in a wide range of organisms.4,6,7) The positive ef-
fects of calorie restriction in humans has also been demonstrated in 
many studies. Calorie restriction while maintaining adequate nutrition 
has beneficial effects such as protecting against the development of 
obesity, cardiovascular disease, hypertension, and cancer.8) In a con-
trolled study, calorie restriction with high levels of physical activity 
showed a decrease in blood pressure, body weight, serum cholesterol 
levels, insulin levels, and other anthropometric and physiological pa-
rameters.9) The mechanisms by which calorie restriction induces life-
extending properties are not fully understood, but the following four 
potential target pathways have been suggested: the activation of AMP 
protein kinase (AMPK)10) and sirtuins,11) inhibition of insulin-like 
growth factor-1 (IGF-1) signaling,12) and inhibition of mammalian tar-
get of rapamycin (mTOR) by rapamycin.13) These pathways are the 
main hypothesized mechanisms of action of calorie restriction that 
control cell growth, mitochondrial function, and autophagy directly or 
indirectly.14) However, despite the proven benefits of calorie restriction, 
it is a difficult technique to successfully use in humans as it is challeng-
ing to apply the treatment long-term, since it requires a high level of 
determination and self-control. This paradox led to the discovery of 
compounds that imitate the outcome of calorie restriction on health 
and lifespan without an actual restriction in calorie intake.15) These 
compounds were named ‘calorie restriction mimetics’ (CRM). Figure 
1 illustrates the schematic mechanisms in relation to CRM.
1. Activator of AMP Protein Kinase
AMPK is activated when cellular energy levels are low, resulting in in-
creased levels of AMP.16) Activation of AMPK regulates whole-body 
Figure 1. Schematic view of the interrelation­
ship between calorie restriction mimetics and 
oxidative stress and their clinical implications 
on longevity. GH, growth hormone; IGF­1, 
insulin­like growth factor­1; PI3K, phosphoi­
nositide 3­kinase; mTOR, mammalian target 
of rapamycin; TSC, tuberous sclerosis 
complex; S6K, S6 kinase; eIF4E, eukaryotic 
initiation factor 4E; 4E­BP1, 4E binding 
protein 1; ROS, reactive oxygen species.
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metabolism. Activation of AMPK resulted in insulin-sensitizing effects 
along with the increased absorption of glucose in skeletal muscles, re-
duced hepatic glucose production, and increased fatty acid oxidation 
in several tissues.16) Metformin, the first-line drug for type 2 diabetes 
mellitus (T2DM), inhibits gluconeogenesis with the activation of 
AMPK in the liver.17) Numerous studies have demonstrated that met-
formin has positive effects on the anti-aging process among patients 
with T2DM.18) In the UK Prospective Diabetes Study, metformin de-
creased the risk of cardiovascular disease,19) cancer incidence, and all-
cause mortality.20) when compared to other anti-diabetic drugs.21) Fur-
thermore, a large retrospective observational study that included over 
180,000 individuals reported that patients with T2DM treated with 
metformin monotherapy lived longer than non-diabetic controls, but 
they did not investigate for a dose-response association.18)
2. Inhibitors of Growth Hormone/Insulin-Like Growth 
Factor-1 Axis
Recent studies have shown that reduced somatotropic activity is relat-
ed to an inhibited rate of aging, delayed onset of age-related diseases, 
and frailty associated with an extended lifespan.22) IGF-1 is secreted by 
the liver in response to growth hormone (GH). Although a deficient 
level of IGF-1 is lethal, several studies have reported that a reduction in 
IGF-1 levels or IGF-1 action has positive effects on protecting against 
cancer, diabetes mellitus, and can extend the lifespan of animal mod-
els.23) Similar results have been shown in GH receptor-deficient Laron 
syndrome patients. Cells/tissues that produce or respond to GH and/
or IGF-1 can be pharmacological targets for lowering IGF-1 action. 
One of the somatostatin analogs decreases serum GH/IGF-1 levels by 
suppressing GH secretion by pituitary somatotrophs. Regrettably, 
these compounds also suppress insulin secretion and have significant 
adverse effects including diarrhea, anorexia, the formation of gall-
stones. Thus, the use of somatostatin analogs as an anti-aging treat-
ment is currently unwarranted. Pegvisomant, another drug for treating 
acromegaly, is the GH receptor antagonist. It inhibits GH action by 
binding to and blocking the GH receptor.24) Pegvisomant has positive 
effects on both longevity and healthy aging by increasing insulin sensi-
tivity and lowering the IGF-1 level. Regarding adverse effects, Trainer 
et al.24) reported that liver enzymes were elevated in a few patients.
3. Inhibitors of Mammalian Target of Rapamycin
The mTOR pathway is another nutrient sensing pathway which induc-
es the lifespan extension effect of calorie restriction. The mTOR is a 
serine/threonine protein kinase that is part of the phosphoinositide 
3-kinase–related kinase family and is found in two protein complexes 
including mTORC1 and mTORC2 with distinct protein components 
and substrates.25) The mTORC1 controls protein translation, autopha-
gy, and various cellular processes through the phosphorylation of sub-
strates such as S6 kinase, 4E binding protein 1, and uncoordinated 51-
like kinase 1. In the presence of sufficient nutrients, mTOR turns off 
stress resistance and autophagy, and subsequently activates transla-
tion.26) Reduced mTOR signaling through genetic or pharmacological 
interventions generated lifespan extension in various species and 
studies are currently being conducted in primates and humans.27)
 Rapamycin is a macrolide and is used as a potent immunosuppres-
sant drug. It is the main antagonist of mTOR signaling. National Insti-
tute on Aging Interventions Testing Programs first reported in 2009 
that rapamycin extends the lifespan of wild-type mice. Since then, nu-
merous studies have confirmed the strong positive effect of rapamycin 
on life span.28) However, rapamycin has significant adverse effects, in-
cluding metabolic dysregulation (e.g., hyperglycemia, hyperinsu-
linemia, and insulin resistance) and proliferative defects in hemato-
poietic lineages.29) These severe side effects limit its consideration and 
clinical use as an anti-aging drug. Safety studies using rapamycin in 
healthy individuals are required in the future.
4. Activators of the Sirtuin Pathway
NAD+ dependent deacetylases known as sirtuins (SIRT 1 to 7) modu-
late the activity of proteins that are related to energy metabolism, stress 
resistance, cell survival, and longevity.30) Sirtuins are homologous to 
yeast silent information regulators (sir2). Overexpression of sir2 ex-
tended the lifespan of yeast, drosophila, and Caenorhabditis elegans.31) 
Although the mechanism by which sirtuins induce anti-aging effects 
has not been fully elucidated, some studies have shown that sirtuins 
promote lifespan by stimulating autophagy. Furthermore, there are re-
ports of sirtuins mediating antioxidant defense, improving mitochon-
drial function, and lowering the serum IGF-1 level.32) Thus, sirtuin acti-
vating compounds have become a target for many anti-aging studies. 
Naturally occurring phytochemicals including, quercetin, myricetin, 
piceatannol, and polyphenols (resveratrol) are known as SIRT-1 ago-
nists.33) The effect of resveratrol on improving health and lifespan have 
been reported in yeast, drosophila, and nematodes.31,34) In other ani-
mal models, resveratrol has failed to promote lifespan, but many 
health benefits have been confirmed.14) Resveratrol improved motor 
performance, bone health, and reduced cardiac failure, seizures, Par-
kinson’s disease, and Alzheimer’s disease.35-40) Resveratrol is also re-
ported to improve memory performance in the elderly and regulate 
glucose and lipid levels in adults with T2DM and obesity.41,42)
HORMONAL REPLACEMENT
Hormone levels decrease with age, and this process is related to de-
creased secretion from the pituitary gland, adrenals, and gonads.43) 
Decreased hormone levels are associated with decreases in bone min-
eral density (BMD), muscle mass, sexual desire, erectile function, and 
intellectual activity. In this context, hormone supplements have been 
widely used to help reverse the effects of aging and improve the quality 
of life in the elderly.
1. Estrogen and Progestins
Two-thirds of women suffer from uncomfortable symptoms like hot 
flashes or vaginal dryness during perimenopause, and HRT is used to 
reduce such symptoms. Estrogens alone, or together with progester-
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one, have positive effects on osteoporosis treatment and have been 
used to prevent vertebral and non-vertebral fractures. However, a 
Women’s Health Initiative (WHI) study reported a higher risk for car-
diovascular disease, thromboembolic event, stroke, and breast cancer 
with a combined treatment of estrogens and progestin.44) Following 
the results of the WHI study, new guidelines recommended hormone 
supplements with lower dose for the shortest amount of time. The 
Food and Drug Administration in the United States suggests using 
HRT only for hot flashes and vaginal dryness.45) HRT can also be used 
for the prevention of osteoporosis when other treatments are not avail-
able.45)
2. Testosterone
Low testosterone levels in older men has been associated with various 
age-associated conditions.46,47) Sarcopenia and osteoporosis are more 
frequent in older men with low plasma testosterone levels.48,49) Fur-
thermore, several studies have demonstrated a relationship between 
low testosterone levels and mild cognitive impairment and Alzheim-
er’s disease.50) Thus, testosterone replacement therapy is beneficial as 
it can increase muscle mass, strength, and BMD in elderly men.51) 
Cognitive function, including verbal, spatial, working memory, and vi-
suospatial function, was improved by testosterone supplementation in 
elderly men.45) One of the adverse effects of testosterone administra-
tion is polycythemia. For this reason, patients undergoing testosterone 
replacement therapy should have their hemoglobin or hematocrit lev-
els checked every 6 months for a total duration of 18 months. Another 
main concern with testosterone replacement therapy is the potential 
risk of aggravating prostate cancer. Animal studies have reported that 
prostate cancer growth was stimulated by testosterone administra-
tion.52) Thus, although recent studies have failed to confirm a relation-
ship between testosterone levels and the risk of prostate cancer, testos-
terone replacement therapy should be seriously reconsidered in pa-
tients with active prostate cancer.53,54) In general, the absolute contrain-
dications of testosterone replacement therapy are as follows: suspect-
ed prostate cancer, severe symptoms of the lower urinary tract such as 
an International Prostate Symptom Score >19, hematocrit >50%, isch-
emic heart disease in the preceding 6 months, poorly controlled con-
gestive heart failure, and untreated sleep apnea.45)
3. Dehydroepiandrosterone
The dehydroepiandrosterone (DHEA) and its metabolite DHEA-sul-
fate are precursors for sex hormones produced by the adrenal gland, 
which are subsequently transformed into androgen or estrogen in the 
target tissue.45) The decline of plasma DHEA levels with age is clinically 
associated with various age-related conditions.55) Since ovarian pro-
duction of estrogen decreases in postmenopausal women, the adrenal 
gland is the only source of estrogen through the peripheral conversion 
of DHEA.56) In previous studies, DHEA supplementation was positively 
associated with muscle mass, muscle strength, physical performance, 
and BMD in both men and women.57-60) Furthermore, DHEA adminis-
tration has demonstrated beneficial effects on mood and sexual func-
tion.61,62) However, the relationship between DHEA and cognitive func-
tion has not been sufficiently researched.45) Recent studies reported 
that low DHEA levels are related to a higher risk for atherosclerosis, 
heart failure, cardiovascular complications, and overall mortality.63) 
Nevertheless, the relationship between DHEA and cardiovascular dis-
ease risk factors is still controversial. The adverse effects of DHEA are 
minimal, such as mild acne, seborrhea, facial hair growth, and ankle 
swelling in women.64,65) There was no significant effect on hormone-
dependent tumors such as breast and prostate cancer,56,66) but longer 
and larger studies are warranted to sufficiently prove the safety of 
DHEA. DHEA is not allowed in the Republic of Korea even though it is 
one of the most widely used anti-aging hormones in the United States.
GUT MICROBIOTA
1. Gut Microbiota
In recent years, the significant role of microbiota in regulating health 
status and lifespan has been demonstrated.2) Microorganisms have 
been shown to affect many essential physiological and metabolic 
functions of host organisms and contribute to the maturation of im-
mune function during early development.67) Healthy gut microbiota 
plays a vital role in resistance to infection, inflammation, autoimmune 
and cancer prevention, and the regulation of the brain-gut axis.68) Re-
cently, many studies have reported evidence that microbiome-target-
ed interventions can have a therapeutic potential not only for age-as-
sociated diseases, but also for slowing down the aging process and for 
promoting longevity. In the gut of individuals living for over 100 years 
(centenarians), the Firmicutes population was rearranged and Proteo-
bacteria was enriched.69) The remodeling of the centenarians’ micro-
biota is also characterized by a substantial decrease in Faecalibacteri-
um prausnitzii and its relatives, which are symbiotics species with pro-
nounced anti-inflammatory activity. Eubacterium limosum and its 
relatives, which are signature bacteria of a long life span, were higher 
in centenarians.69) Another centenarian study reported that genes in-
volved in short-chain fatty acid synthesis and the saccharolytic poten-
tial are decreased, while proteolytic functions of the intestinal metage-
nome were increased in elderly people compared to younger adults.70) 
However, microbiota composition can be profoundly influenced by 
several confounding factors including diet, prebiotics, level of physical 
activity, drug use, and exposure to psychological stressors. Therefore, 
any interpretation of the results should take these confounding vari-
ables into account.
2. Fecal Microbiota Transplantation
Microbiota-targeted interventions include prebiotics and probiotics, 
particularly those containing Bifidobacterium and Lactobacillus.71,72) 
The probiotic Lactobacillus rhamnosus GG ATCC 53103 has been 
shown to promote the anti-inflammatory pathways of resident micro-
organisms.73) Fecal microbiota transplantation (FMT) is a radical man-
agement program that is used to restore the intestinal ecosystem 
through the transferring of liquid filtrate feces from a healthy donor 
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into the recipient’s gastrointestinal tract.74) FMT has been used as a 
therapeutic option for Clostridium difficile infection.75) More recently, 
however, its potential benefit and safety have been demonstrated in 
non-gastrointestinal diseases, including those commonly associated 
with aging, T2DM, metabolic syndrome, atherosclerosis, and neuro-
degenerative diseases.68,76) Despite the great therapeutic potential of 
the FMT procedure, its implementation in clinical practice is limited 
by several concerns. These concerns include problems with donor 
screening, the limited viability of fresh stool samples, fears about po-
tential pathogen transmission, lack of a standardized treatment regi-
men, and patients not consenting to be treated.76)
VITAMIN D
Vitamin D is a significant pro-hormone for optimal intestinal calcium 
absorption for the mineralization of bone.77) Recently, many studies 
have revealed numerous positive effects of vitamin D use in the elderly 
population. Vitamin D deficiency in the elderly is associated with de-
creased cognitive function, a higher risk of Alzheimer’s disease,78) loss 
of muscle mass and function,79) and osteoporosis. Cross-sectional 
studies have demonstrated that a low level of vitamin D is related to a 
higher risk of cardiovascular diseases such as hypertension, heart fail-
ure, and ischemic heart disease.80,81) However, the effects of vitamin D 
as a supplement are still controversial. One study demonstrated that a 
high serum vitamin D concentration is associated with high athero-
sclerosis cardiovascular disease risk scores.82)
 Since vitamin D production is usually stimulated by adequate sun 
exposure, vitamin D levels tend to be lower in elderly people with re-
duced outside activity. Vitamin D therapy in the elderly was shown to 
improve muscle mass and performance, and to a reduced the rate of 
falls.79) Furthermore, a recent study reported that vitamin D also has an 
anti-cancer effect by inhibiting cancer cell growth in several types of 
cancer.83) In this regard, numerous agencies and scientific organiza-
tions have developed recommendations for vitamin D therapy and 
also provide guidance on optimal serum 25-hydroxyvitamin D 
(25[OH]D) concentrations. The general target for the 25(OH)D con-
centration is above 30 ng/mL, and the replacement dose can vary, 
ranging from between 400 and 2,000 IU/d depending on age, body 
weight, disease status, and ethnicity.84) Vitamin D intake through natu-
ral food sources such as milk, beverages made from soy, almonds, and 
coconuts is also important in elderly people with low vitamin D lev-
els.84)
CONCLUSION
Anti-aging medicine is a growing field in locations with an aging popu-
lation, particularly in developed countries. Available anti-aging inter-
ventions are categorized in Table 1 according to their mechanisms of 
action. CRM define compounds that imitate the outcome of calorie re-
striction, and these include the activator of AMPK (metformin), inhibi-
tor of GH/IGF-1 axis (pegvisomant), inhibitor of mTOR (rapamycin), 
and activator of the sirtuin pathway (resveratrol). Hormonal replace-
ment such as estrogen, progestin, testosterone, and DHEA in the el-
derly have been widely used to improve various symptoms associated 
with frailty, body composition, cardiometabolic diseases, neurodegen-
erative diseases, and quality of life. Since HRT can increase the risk of 
thromboembolism or some types of cancer, it should be used with 
precautions. The composition of healthy gut microbiota through pre-
biotic/probiotics and FMT has a great potential for anti-aging medi-
cine. Furthermore, vitamin D is expected to be a main anti-aging med-
icine in the near future due to its numerous positive effects in elderly 
population.
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